Zobrazeno 1 - 10
of 35
pro vyhledávání: '"CG Rodriguez-Gonzalez"'
Autor:
FJ García-Moreno, Roberto Collado-Borrell, María Olmedo, Maricela Valerio, Elena Lobato-Matilla, Beatriz Somoza-Fernandez, Ana Herranz, Juan Carlos Lopez-Bernaldo-de-Quirós, Teresa Aldámiz-Echevarría, Silvia Manrique-Rodríguez, Emilio Bouza, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, RM Romero-Jiménez, Marina Machado, Paula Ruiz-Briones, Patricia Muñoz, Cecilia M. Fernández-Llamazares, Rafael Correa-Rocha, Milagros Sancho-Gonzalez, José Luis Revuelta-Herrero, Camino Sarobe-González, Alvaro Gimenez-Manzorro, CG Rodriguez-Gonzalez, Esther Chamorro-de-Vega, María Sanjurjo
Publikováno v:
Expert Review of Clinical Pharmacology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c533ed6110c4c54469cd542550b561ee
Autor:
Álvaro Giménez-Manzorro, María Sanjurjo, CG Rodriguez-Gonzalez, Esther Chamorro-de-Vega, Ana Herranz
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 77(6)
Purpose The design, implementation, and assessment of a comprehensive pharmaceutical care program (CPCP) for hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAA) are described. Summary The advent of DAA regimens has c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e7b87c07ba3c01c535bd912c2118fc
https://pubmed.ncbi.nlm.nih.gov/31811290
https://pubmed.ncbi.nlm.nih.gov/31811290
Autor:
Maria Luisa Martin-Barbero, Sara Ibáñez-García, María Sanjurjo-Sáez, Ana Herranz-Alonso, CG Rodriguez-Gonzalez, E Chamorro-De Vega, JL de la Rosa
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Clinical decision support systems (CDSS) can play an important role in facilitating antimicrobial stewardship programmes (ASP). However, the effects of CDSS in improving antimicrobial therapy have been insufficiently studied. Purpose To ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e7a73d3f72a4d94780536883938d88
https://doi.org/10.1136/ejhpharm-2019-eahpconf.466
https://doi.org/10.1136/ejhpharm-2019-eahpconf.466
Autor:
María Sanjurjo-Sáez, José Luis Revuelta-Herrero, Vicente Escudero-Vilaplana, Irene Iglesias-Peinado, Eva González-Haba, Sara Ibáñez-García, E García Martín, Ana Herranz, CG Rodriguez-Gonzalez, B. Marzal Alfaro
Publikováno v:
Section 3: Production and Compounding.
Background The implementation of technology for chemotherapy compounding is recommended by several organisations to improve patient safety. However, a careful evaluation of their benefits and risks is needed. Purpose To evaluate the safety before and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e7249eef896daa7d45eb6bef8bff5d4
https://doi.org/10.1136/ejhpharm-2019-eahpconf.104
https://doi.org/10.1136/ejhpharm-2019-eahpconf.104
Autor:
CG Rodriguez-Gonzalez, María Olmedo, Maricela Valerio, María Sanjurjo-Sáez, Ana Herranz-Alonso, E Chamorro-De Vega, ME Rochet, Patricia Muñoz
Publikováno v:
Section 6: Education and Research.
Background Dalbavancin (DAL) has recently been approved to treat complicated skin and soft tissue infections. It enables treatments with a single IV administration, so it is a highly attractive option in other infections that requires long-term treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db9ba76ac2bb94444d5fb305be11aaa1
https://doi.org/10.1136/ejhpharm-2019-eahpconf.604
https://doi.org/10.1136/ejhpharm-2019-eahpconf.604
Autor:
S García Sánchez, P Muñoz-García De Paredes, E Chamorro-De Vega, E Bouza-Santiago, E García-Martín, FJ García-Moreno, María Sanjurjo-Sáez, M Valerio Minero, CG Rodriguez-Gonzalez, Ana Herranz-Alonso
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The use of daptomycin has increased in Spain since its approval and there is a great variability in the dosage and the criteria for its use in clinical practice. Purpose This study was aimed at reporting the real use of daptomycin in clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7073a9d784366277487d67399c0cd8d2
https://doi.org/10.1136/ejhpharm-2019-eahpconf.202
https://doi.org/10.1136/ejhpharm-2019-eahpconf.202
Autor:
FJ García-Moreno, María Sanjurjo-Sáez, Xandra García-González, C Ortega-Navarro, Vicente Escudero-Vilaplana, Irene Iglesias-Peinado, CG Rodriguez-Gonzalez, E González-Haba Peña, B. Marzal Alfaro, Sara Ibáñez-García, Ana Herranz
Publikováno v:
Eur J Hosp Pharm
Background Antineoplastic preparation presents unique safety concerns because of its toxicity and narrow therapeutic window. Moreover, the antineoplastic use system includes several stages that are vulnerable to opportunities for potentially harmful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2650b9910dd09d472402117f10e252bf
https://doi.org/10.1136/ejhpharm-2018-eahpconf.421
https://doi.org/10.1136/ejhpharm-2018-eahpconf.421
Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration
Autor:
Ana Herranz-Alonso, A. de Lorenzo-Pinto, Alvaro Gimenez-Manzorro, M. B. Marzal-Alfaro, María Sanjurjo-Sáez, A. Ahumada-Jiménez, CG Rodriguez-Gonzalez
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 41:444-446
SummaryWhat is known and objective Limited data are available on co-administration of acenocoumarol with direct-acting antiviral agents for chronic hepatitis C virus infection. Case summary We report a case of a patient who required a significant inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::024fd84c309277f1a3a9512ee5e59b62
https://doi.org/10.1111/jcpt.12403
https://doi.org/10.1111/jcpt.12403
Autor:
E Chamorro de Vega, C Ortega-Navarro, C Ruiz-Martínez, Alvaro Gimenez-Manzorro, Ana Herranz-Alonso, Vicente Escudero-Vilaplana, María Sanjurjo-Sáez, CG Rodriguez-Gonzalez, Roberto Collado-Borrell
Publikováno v:
Clinical pharmacy.
Background Currently, oral antineoplastic agents (OAA) represent approximately 40% of all chemotherapy agents. Thus, onco-haematological outpatients have acquired more autonomy and responsibility since OAA require self-administration at home. Hospita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d77db59b4c4fb0e994494c9045f4be37
https://doi.org/10.1136/ejhpharm-2017-000640.162
https://doi.org/10.1136/ejhpharm-2017-000640.162
Autor:
Cristina Pérez-Sanz, CG Rodriguez-Gonzalez, Francisco Fernández-Avilés, Begoña Cuéllar-Basterrechea, A. de Lorenzo-Pinto, Héctor Bueno, Irene Iglesias-Peinado, María Sanjurjo-Sáez, Ana Herranz-Alonso
Publikováno v:
International journal of clinical practice. 70(2)
Aim The aim of the study was to evaluate the effectiveness of a multidisciplinary intervention to reduce the risk of bleeding associated with antithrombotic drugs in patients with acute coronary syndrome (ACS). Methods We designed a pre-post quasi-ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1199a9f23e30a3ba672d3eb7b8ad9d26
https://pubmed.ncbi.nlm.nih.gov/26709847
https://pubmed.ncbi.nlm.nih.gov/26709847